Technology

The company also reported Q3 2024 earnings, noting total revenue of $76.4 million, adjusted EBITDA of $7.3 million and a net loss of $14.7 million.

The acquisition includes all of NeuroReality's assets, including its flagship rehabilitation product, Koji's Quest.

The company will use the funds to expand in Asian and U.S. markets, advance its AI algorithms and grow its workforce.

The funding will support clinical trials for the company's NeuroHawk brain-scanning device.  

The company reported a 77% YOY increase in revenue in Q3 2024 and plans to release a generic version of Novo Nordisk's GLP-1 drug on its platform in 2025.

The company offers a marketplace for individuals seeking addiction and mental health treatment. It will use the funds to scale its workforce and expand its reach.

This marks AITRICS's first foray into Southeast Asia, with applications for regulatory clearance in Indonesia and Malaysia underway. 

The aim is to attract government and healthcare experts who can gain a better understanding of digitalization in healthcare.

He has boasted about the accuracy of subscription-based Grok artificial intelligence for analyzing medical images, but physicians and researchers say the model's ability to diagnose medical conditions is limited, and privacy experts have concerns.  

The CRISPR therapy, HG202, was conceived using AI and machine learning and aims to treat individuals with neovascular age-related macular degeneration.